Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | PGK1 | P00558 | 3/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.34 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 5/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.33 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244462 | 0.94 | CA12 (0.33) | TLR7PGK1EHMT2EHMT1CA12 | |
| SCHEMBL2246222 | 0.90 | TLR7 (0.42) | TLR7TLR9PGK1EHMT2KDM1A | |
| SCHEMBL2249570 | 0.86 | TLR7 (0.34) | TLR7TLR9PGK1EHMT2KDM1A | |
| SCHEMBL2246147 | 0.84 | TLR7 (0.35) | TLR7TLR9PGK1EHMT2KDM1A | |
| SCHEMBL2244520 | 0.83 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL2245419 | 0.82 | CA12 (0.50) | PGK1CA12CA1CA2CA9 | |
| SCHEMBL2246095 | 0.81 | KDM4E (0.42) | EHMT2KDM1ARCOR1 | |
| SCHEMBL2246125 | 0.79 | EHMT2 (0.32) | TLR7EHMT2KDM1ARCOR1EHMT1 | |
| SCHEMBL2244447 | 0.79 | HRH3 (0.42) | EHMT2KDM1ARCOR1 | |
| SCHEMBL2244540 | 0.78 | BCHE (0.41) | EHMT2KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | claimed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | claimed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | claimed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | TLR7 3161/4885TLR9 4192/4885PGK1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.